Compositions and methods for treatment of hematological malignancies
View Patent ↗Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.
1. A method of treating multiple myeloma, benign plasma cell disorder or premalignant forms of multiple myeloma in a subject, comprising administering to the subject a CD40-FasL chimeric protein, wherein cells of said multiple myeloma, said benign plasma cell disorder or said premalignant forms of multiple myeloma express CD40L.
2. The method of claim 1 , wherein said multiple myeloma is selected from the group consisting of multiple myeloma cancers which produce light chains of kappa-type and/or light chains of lambda-type; aggressive multiple myeloma; smoldering multiple myeloma (SMM), indolent multiple myeloma, and primary amyloidosis.
3. The method of claim 2 , wherein said aggressive multiple myeloma is primary plasma cell leukemia (PCL).
4. The method of claim 1 , wherein said benign plasma cell disorder is selected from the group consisting of MGUS (monoclonal gammopathy of undetermined significance) and/or Waldenstrom's macroglobulinemia (WM, also known as lymphoplasmacytic lymphoma) which may proceed to multiple myeloma.
5. The method of claim 4 , to halt the progression of the benign plasma cell disorder to a malignant form of multiple myeloma.
6. The method of claim 1 , wherein said chimeric protein is administered as a pharmaceutical composition comprising said chimeric protein and a
pharmaceutical carrier, adapted for treatment of said multiple myeloma, said benign plasma cell disorder or said premalignant forms of multiple myeloma.
7. The method of claim 6 , wherein said multiple myeloma is selected from the group consisting of multiple myeloma cancers which produce light chains of kappa-type and/or light chains of lambda-type; aggressive multiple myeloma; smoldering multiple myeloma (SMM), indolent multiple myeloma, and primary amyloidosis.
8. The method of claim 7 , wherein said multiple myeloma is primary plasma cell leukemia (PCL).
9. The method of claim 6 , wherein said benign plasma cell disorder is selected from the group consisting of MGUS (monoclonal gammopathy of undetermined significance) and/or Waldenstrom's macroglobulinemia (WM, also known as lymphoplasmacytic lymphoma) which may proceed to multiple myeloma.
10. The method of claim 9 , to halt the progression of the benign plasma cell disorder to a malignant form of multiple myeloma.
11. A method of treating multiple myeloma, benign plasma cell disorder or premalignant forms of multiple myeloma in a subject, comprising administering to the subject a CTLA4-FasL chimeric protein.
12. The method of claim 11 , wherein cells of said multiple myeloma, said benign plasma cell disorder or said premalignant forms of multiple myeloma express B7.
13. The method of claim 11 , wherein said multiple myeloma is selected from the group consisting of multiple myeloma cancers which produce light chains of kappa-type and/or light chains of lambda-type; aggressive multiple myeloma; smoldering multiple myeloma (SMM), indolent multiple myeloma, and primary amyloidosis.
14. The method of claim 13 , wherein said aggressive multiple myeloma is primary plasma cell leukemia (PCL).
15. The method of claim 11 , wherein said benign plasma cell disorder is selected from the group consisting of MGUS (monoclonal gammopathy of undetermined significance) and/or Waldenstrom's macroglobulinemia (WM, also known as lymphoplasmacytic lymphoma) which may proceed to multiple myeloma.
16. The method of claim 15 , to halt the progression of the benign plasma cell disorder to a malignant form of multiple myeloma.
17. The method of claim 11 , wherein said chimeric protein is administered as a pharmaceutical composition comprising said chimeric protein and a pharmaceutical carrier, adapted for treatment of said multiple myeloma, said benign plasma cell disorder or said premalignant forms of multiple myeloma.
18. The method of claim 17 , wherein cells of said multiple myeloma, said benign plasma cell disorder or said premalignant forms of multiple myeloma express B7.
19. The method of claim 17 , wherein said multiple myeloma is selected from the group consisting of multiple myeloma cancers which produce light chains of kappa-type and/or light chains of lambda-type; aggressive multiple myeloma; smoldering multiple myeloma (SMM), indolent multiple myeloma, and primary amyloidosis.
20. The method of claim 19 , wherein said multiple myeloma is primary plasma cell leukemia (PCL).
21. The method of claim 11 , wherein said benign plasma cell disorder is selected from the group consisting of MGUS (monoclonal gammopathy of undetermined significance) and/or Waldenstrom's macroglobulinemia (WM, also known as lymphoplasmacytic lymphoma) which may proceed to multiple myeloma.
22. The method of claim 21 , to halt the progression of the benign plasma cell disorder to a malignant form of multiple myeloma.